Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Newcastle Private Hospital, New Lambton Heights

Tasman Oncology Research, Southport

Cancer Research SA, Adelaide

Southern Oncology Clinical Research Unit, Bedford Park

Memorial Sloan Kettering Cancer Center, New York

Pennsylvania Cancer Specialists & Research Institute (Formerly Gettysburg Cancer Center), Gettysburg

MedStar Georgetown University Hospital, Washington D.C.

The Center for Cancer and Blood Disorders, Bethesda

Greater Baltimore Medical Center, Baltimore

NEXT/Virginia Cancer Specialists, Fairfax

Prisma Health, Greenville

Emory University Winship Cancer Institute, Atlanta

University of Florida Health Cancer Center, Gainesville

AdventHealth Cancer Institute, Orlando

Memorial Cancer Institute, Pembroke Pines

Florida Cancer Specialists, Atlantis

Ocala Oncology Florida Cancer Affiliates, Ocala

Tennessee Oncology - Nashville, Nashville

Tennessee Oncology Chattanooga Memorial Plaza, Chattanooga

Norton Health, Lexington

The Ohio State University James Cancer Center, Columbus

Zangmeister Cancer Center, Columbus

University of Cincinnati Medical Center, Cincinnati

University of Michigan Medical Center, Ann Arbor

Highlands Oncology Group, Springdale

Houston Methodist Cancer Center, Houston

Oncology Consultants, Houston

University of Colorado Hospital, Aurora

University of Utah Huntsman Cancer Institute, Salt Lake City

The Oncology Institute of Hope and Innovation, Downey

City of Hope Cancer Center, Duarte

University of California at Davis, Davis

University of Washington / Fred Hutchinson Cancer Center, Seattle

Nuvance Health, Norwalk

Dana Farber Cancer Institute, Boston

Massachusetts General Hospital, Boston

Atlantic Healthcare System, Morristown